万泰生物
(603392)
| 流通市值：696.32亿 | | | 总市值：696.32亿 |
| 流通股本：12.65亿 | | | 总股本：12.65亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,498,369,947.13 | 843,561,860.09 | 400,625,153.87 | 2,245,403,245.65 |
| 营业收入 | 1,498,369,947.13 | 843,561,860.09 | 400,625,153.87 | 2,245,403,245.65 |
| 二、营业总成本 | 1,780,002,318.88 | 1,020,748,464.07 | 464,970,086.22 | 2,395,621,317.62 |
| 营业成本 | 695,514,313.91 | 334,452,600.67 | 134,003,165.48 | 759,044,722.33 |
| 税金及附加 | 13,204,225.16 | 11,084,588.3 | 2,204,754.82 | 23,100,236.89 |
| 销售费用 | 347,802,633.94 | 217,080,093.66 | 103,473,018.76 | 438,392,131.59 |
| 管理费用 | 289,303,494.75 | 192,690,508.21 | 92,912,751.33 | 347,100,195.32 |
| 研发费用 | 445,519,959.69 | 276,466,361.42 | 138,625,170.95 | 886,051,943.23 |
| 财务费用 | -11,342,308.57 | -11,025,688.19 | -6,248,775.12 | -58,067,911.74 |
| 其中:利息费用 | 5,149,053.08 | 13,605,360.7 | 2,026,170.05 | 8,324,928.73 |
| 其中:利息收入 | 17,628,843.51 | 25,462,600.15 | 6,681,311.33 | 59,455,687.13 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 23,076,254.44 | 17,591,273.78 | 8,817,746.15 | 36,707,335.76 |
| 加:投资收益 | 66,510,992.9 | 44,357,628.65 | 22,017,103.25 | 109,636,079.11 |
| 资产处置收益 | -51,055.19 | -146,644.6 | -15,909.99 | 7,923,472.52 |
| 资产减值损失(新) | -16,894,151.74 | -23,426,159.84 | -5,497,838.89 | -103,626,312.79 |
| 信用减值损失(新) | -49,990,223.77 | -57,429,999.74 | -45,828,090.79 | -17,171,300.92 |
| 其他收益 | 74,538,821.37 | 56,896,996.43 | 29,055,479.16 | 210,586,461.02 |
| 四、营业利润 | -184,441,733.74 | -139,343,509.3 | -55,796,443.46 | 93,837,662.73 |
| 加:营业外收入 | 678,368.2 | 588,873.86 | 135,532.11 | 2,629,833.14 |
| 减:营业外支出 | 8,093,057.21 | 6,928,222.47 | 2,239,304.55 | 28,986,662.99 |
| 五、利润总额 | -191,856,422.75 | -145,682,857.91 | -57,900,215.9 | 67,480,832.88 |
| 减:所得税费用 | -17,965,068.19 | -190,628.13 | -3,758,229.48 | -41,613,689.49 |
| 六、净利润 | -173,891,354.56 | -145,492,229.78 | -54,141,986.42 | 109,094,522.37 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -173,891,354.56 | -145,492,229.78 | -54,141,986.42 | 109,094,522.37 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -173,421,950.63 | -144,038,127.02 | -52,776,946.91 | 106,235,425.64 |
| 少数股东损益 | -469,403.93 | -1,454,102.76 | -1,365,039.51 | 2,859,096.73 |
| 扣除非经常损益后的净利润 | -307,618,892.32 | -242,605,985.91 | -105,032,198.13 | -186,442,703.9 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.14 | -0.11 | -0.04 | 0.08 |
| (二)稀释每股收益 | -0.14 | -0.11 | -0.04 | 0.08 |
| 九、综合收益总额 | -173,891,354.56 | -145,492,229.78 | -54,141,986.42 | 109,094,522.37 |
| 归属于母公司股东的综合收益总额 | -173,421,950.63 | -144,038,127.02 | -52,776,946.91 | 106,235,425.64 |
| 归属于少数股东的综合收益总额 | -469,403.93 | -1,454,102.76 | -1,365,039.51 | 2,859,096.73 |
| 公告日期 | 2025-10-30 | 2025-08-21 | 2025-04-25 | 2025-04-12 |
| 审计意见(境内) | | | | 标准无保留意见 |